NCT03805932 2025-07-24
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
Clinical Trials
5 trialsNCT03501615 2020-06-29
MOXE
AstraZeneca
Approved for marketing
NCT01829711 2020-04-08
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
MedImmune LLC
Phase 3 Completed
NCT00586924 2019-04-02
A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
MedImmune LLC
Phase 1 Completed
NCT00462189 2007-04-18
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Cambridge Antibody Technology
Phase 1 Unknown